Physician profile
Pradeep Mehra
NPI 1447299474
$2,523.22
in general payments reported to CMS, 2019-2025
17 companies · $299 in 2025
The $299 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $36.86 · 2021: $462 · 2022: $762 · 2023: $449 · 2024: $201 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $933 · Education: $15.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $933.41 |
| Education | $15.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $368.50 | 2021-2023 | Krystexxa |
| Abbott Laboratories | $352.28 | 2021-2023 | Cardiomems |
| Travere Therapeutics, INC. | $306.70 | 2022 | |
| Aurinia Pharma U.S., INC. | $232.54 | 2021 | |
| Calliditas Therapeutics US INC. | $207.76 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $180.67 | 2019-2022 | |
| Amgen INC. | $159.38 | 2023-2025 | Krystexxa, Aranesp, Parsabiv |
| Baxter Healthcare | $123.64 | 2024 | |
| Opko Pharmaceuticals, LLC | $116.25 | 2019-2025 | Rayaldee |
| Janssen Pharmaceuticals, INC | $114.39 | 2023 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $107.20 | 2019-2022 | |
| Vantive US Healthcare LLC | $104.90 | 2025 | |
| Vifor Pharma, INC. | $43.49 | 2021-2023 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.58 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $29.39 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $21.73 | 2024 | Acthar |
| Astrazeneca Pharmaceuticals LP | $15.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradeep Mehra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.